No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ZTS240517P145000
- 0.10
- -0.05-33.33%
15min DelayClose May 10 15:54 ET
0.50High0.10Low
0.50Open0.15Pre Close54 Volume4.20K Open Interest145.00Strike Price1.35KTurnover58.07%IV-14.30%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type-0.0240Delta0.0042Gamma1352.32Leverage Ratio-0.0492Theta-0.0007Rho-32.46Eff Leverage0.0131Vega
Intraday
- 5D
- 1D
News
Express News | NYSE Order Imbalance 56002.0 Shares on Buy Side
Express News | NYSE Order Imbalance 122635.0 Shares on Buy Side
Zoetis Is Maintained at Buy by HSBC
Zoetis Is Maintained at Buy by HSBC
Zoetis Price Target Cut to $225.00/Share From $230.00 by HSBC
Zoetis Price Target Cut to $225.00/Share From $230.00 by HSBC
HSBC Maintains Buy on Zoetis, Lowers Price Target to $225
HSBC analyst Morten Herholdt maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target from $230 to $225.
HSBC Adjusts Price Target on Zoetis to $225 From $230
Zoetis (ZTS) has an average rating of outperform and price targets ranging from $170 to $248, according to analysts polled by Capital IQ.
Comments
$Zoetis(ZTS.US$ I got an call option a month out on friday soon as I heard the news!
1
2
Zoetis' market sentiment remains steady, with share price reflecting EPS growth. Over five years, returns improve, indicating the share price may pause as the business pursues its growth strategy.
Piper Sandler analysts find Boston Scientific, Expedia Group, Progressive Corporation, Skechers U.S.A., Synovus Financial, and Zoetis Inc. stocks attractive due to their individual strengths and positive trends.
The stock shows promising signs with profitable growth and substantial insider ownership, indicating aligned interests between shareholders and management. Investors are advised to keep Zoetis on their watchlist while also being aware of any potential warning signs.
Read more